COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that Peter Friedli, Chairman of the Board of Directors of Osiris, and certain entities with which he is affiliated, entered into an Amendment to the Lock-up Agreement with Osiris originally commencing on October 30, 2006. Pursuant to the Amended Lock-up Agreement, the parties have agreed not to transfer Company securities held by them without approval of the Company until January 30, 2009, rather than and in lieu of January 30, 2008, as provided in the Original Lock-Up Agreement. The extended lock-up agreement covers 12.9 million shares of Osiris common stock, and warrants and shares issuable if and when convertible promissory notes are converted into common stock for an additional 1.5 million shares of common stock.
